Home › Funds › Affinity Asset Advisors, LLC › OVID
Affinity Asset Advisors, LLC position in OVID
OVID THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 10,144,562 shares of OVID (OVID THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.3M, representing 1.18% of its reported portfolio and ranking #23 among its reported holdings. Affinity Asset Advisors, LLC has disclosed OVID holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's OVID position evolved
Affinity Asset Advisors, LLC first disclosed a stake in OVID in Q1 2025 at 667,516 shares (US$208K). The position peaked in Q2 2026 at 10,144,562 shares, worth US$27.3M. Across 7 filings, Affinity Asset Advisors, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 10,144,562 shares valued at US$25.3M. Notable position changes include a 297% increase in Q3 2025 (shares rose 25% over the following quarter), a 170% increase in Q4 2025 (shares rose 36% over the following quarter), a 49% increase in Q1 2026 (shares rose 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 667.52K | $208.20K | New |
| Q2 2025 | 667.52K | $220.21K | Hold |
| Q3 2025 | 2.65M | $3.44M | Add |
| Q4 2025 | 7.15M | $11.65M | Add |
| Q1 2026 | 10.64M | $23.61M | Add |
| Q2 2026 | 10.14M | $27.29M | Reduce |
| Q3 2026 | 10.14M | $25.26M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OVID and 13F data
OVID (OVID THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in OVID — the largest reported positions include ADAR1 Capital Management, LLC (US$20.0M), SILVERARC CAPITAL MANAGEMENT, LLC (US$14.8M), STEMPOINT CAPITAL LP (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OVID
- ADAR1 Capital Management, LLC 7.42M sh · $19.95M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.95M sh · $14.82M · Q3 2026
- STEMPOINT CAPITAL LP 2.42M sh · $6.50M · Q2 2026
- Ikarian Capital, LLC 2.27M sh · $6.11M · Q2 2026
- Rosalind Advisors, Inc. 1.11M sh · $2.98M · Q2 2026
- Sio Capital Management, LLC 1.01M sh · $2.70M · Q2 2026
- Propel Bio Management, LLC 1.02M sh · $2.54M · Q3 2026
- Saturn V Capital Management LP 663.06K sh · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K sh · $1.68M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held OVID?
Affinity Asset Advisors, LLC has disclosed OVID holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Affinity Asset Advisors, LLC's current position in OVID?
As of Q3 2026, Affinity Asset Advisors, LLC holds 10.14M shares of OVID (OVID THERAPEUTICS INC), valued at $25.26M, representing 1.18% of its reported portfolio and ranking #23.
Has Affinity Asset Advisors, LLC been buying or selling OVID?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in OVID. The position peaked in Q2 2026 at 10.14M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include ADAR1 Capital Management, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, STEMPOINT CAPITAL LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.